A pituitary adenoma is a benign, typically slow-growing neoplasm arising from the hormone-producing cells of the anterior pituitary gland. The pituitary is a pea-sized endocrine organ located within the sella turcica at the skull base and functions as a central regulator of the endocrine system. Through its trophic hormones, it regulates growth, metabolism, thyroid function, adrenal function, and gonadal and
reproductive function.
Pituitary adenomas account for approximately 10–15% of primary intracranial tumors and are among the most common neoplasms of the sellar region. Autopsy studies have demonstrated small, clinically silent pituitary adenomas in up to approximately 20% of the population. They may occur at any age, with the highest incidence between 30 and 60 years. Pituitary adenomas are classified according to two principal criteria:
Pituitary adenomas are almost invariably benign and do not metastasize. Many microadenomas are discovered incidentally on MRI and, in the absence of clinically relevant hormonal hypersecretion or progressive growth, may initially be managed conservatively.
The clinical manifestations of a pituitary adenoma arise through two principal mechanisms: hormone hypersecretion in functioning adenomas and local mass effect caused by tumor growth.
The optimal treatment strategy depends on adenoma subtype, tumor size and extent, hormonal activity, clinical symptoms, the patient's general medical condition, and individual preferences. Treatment decisions are generally made within an interdisciplinary team involving endocrinology,
neurosurgery, neuroradiology, ophthalmology, and radiosurgery/radiation oncology.
Stereotactic radiosurgery is an established non-invasive treatment option for selected pituitary adenomas, particularly when residual tumor remains after surgery, when recurrent or progressive disease develops, or when further surgery is not feasible or is not desired. A principal advantage of radiosurgical treatment at the European Radiosurgery Center Munich is the ability to deliver radiation with submillimeter precision while minimizing exposure of adjacent healthy tissues and critical structures, particularly the optic nerves, optic chiasm, hypothalamus, pituitary stalk, and brainstem.
Treatment is performed on an outpatient basis, is painless, and does not require general anesthesia. In appropriately selected cases, treatment can be completed in a single radiosurgical session.
The ERCM has treated approximately 400 patients with pituitary adenomas and has more than 20 years of experience in stereotactic radiosurgery. CyberKnife® and ZAP-X® deliver highly focused photon beams from multiple directions. The individual beam paths converge on the defined target volume, creating a high biologically effective dose within the adenoma while maintaining a steep dose gradient toward surrounding normal tissue.
For non-functioning pituitary adenomas, long-term local tumor control after radiosurgery exceeds 90% in published series. In functioning adenomas such as acromegaly and Cushing disease, endocrine remission or biochemical normalization may be achieved in a substantial proportion of patients, although the probability and time to remission depend on adenoma subtype, baseline hormone levels, prior treatments, and radiosurgical dose. Local tumor control is likewise generally high.
The availability of several effective treatment modalities means that the choice of therapy should always take the individual clinical situation and the patient's personal circumstances into account. We support patients in this decision-making process and provide individualized, non-binding specialist advice.
A pituitary adenoma is a benign neoplasm arising from the pituitary gland, a small endocrine organ located at the skull base that regulates numerous physiological functions through hormone secretion. Pituitary adenomas are among the most common tumors of the sellar region and do not metastasize. Depending on their subtype, they may produce excessive amounts of one or more pituitary hormones (functioning adenomas) or cause symptoms predominantly through local tumor growth and mass effect (non-functioning adenomas).
The clinical presentation varies according to tumor subtype, size, and anatomical extension. Common manifestations include:
No. Small, non-functioning microadenomas without symptoms or relevant growth may initially be managed with active surveillance. The need for treatment depends on:
In most cases, radiosurgery does not result in immediate physical restrictions. Follow-up includes regular pituitary MRI and endocrine laboratory assessment according to the individual treatment plan. Because the biological effects of radiosurgery develop gradually over months and radiographic tumor regression may be slow, structured endocrinological follow-up is particularly important. Long-term surveillance is also required to identify delayed pituitary hormone deficiencies.
Recurrence after complete surgical resection is uncommon but can occur, particularly when complete removal is not possible because of cavernous sinus invasion or proximity to critical neurovascular structures. Stereotactic radiosurgery is a highly effective treatment option for residual or recurrent pituitary adenoma, with long-term local control rates exceeding 90% for non-functioning adenomas in published series.